Navigation Links
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
Date:4/28/2009

abetes, cardiovascular disease and metabolic syndrome.

NEBIDO(R) is a registered trademark of Bayer Schering Pharma.

ABOUT ENDO

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP).Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; Sanctura(R) and its XR version for treatment of overactive bladder, Vantas(R) for the palliative treatment of advanced prostate cancer, and Supprelin(R) for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securiti
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity
2. Womens Testosterone Patch May Not Work
3. Prostate cancer drug reduces testosterone levels in as little as 3 days
4. Study shows testosterone improves sexual well-being in post-menopausal women
5. Testosterone Patch Restores Libido in Postmenopausal Women
6. Testosterone key to disease transmission
7. AUDIO from Medialink and Solvay: Men Suffering From Symptoms of Low Testosterone Should Talk to Their Doctor
8. Studies Support Testosterone Supplements for Older Men
9. Gamma Labs to Boost Testosterone At World Series of Poker In Las Vegas
10. Men With Low Testosterone Not Receiving Treatment
11. Many men with low testosterone levels do not receive treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Cooking and ... 3.1 out of 5. This score reflects slightly positive ... of product specialization, low switching costs and a low ... by the low availability of substitutes for cooking and ... of steel and aluminum, key inputs in the production ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... University and Harvard University have collaboratively developed a new theoretical ... sequences, even though there are many obstacles in the way ... in the scientific journal Nature Physics . , In ... so that different cells carry out the right tasks at ...
... important tasks of the immune system is to identify what ... then the body,s own structures will be attacked, the result ... mellitus type 1 or multiple sclerosis. The only way to ... that turn against the body,s own tissue in other ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced that shareholders ... of Tepnel by Gen-Probe by the requisite majorities at Court ... of Tepnel shareholders voted in favor of the acquisition, which ... as a "scheme of arrangement" under English law. The ...
... Probiotic Works Naturally to Restore Oral HealthCHICAGO, March ... and Butler(R) brand products, has introduced GUM(R) PerioBalance(TM), ... for oral health. GUM(R) PerioBalance(TM) is available online ... GUM(R) PerioBalance(TM) e-store ( www.periobalance.com ) and at ...
... Health Segment Increases Annual RevenueLOVELAND, Colo., March 16 ... ("Heska" or the "Company") today reported financial results ... December 31, 2008, and year ended December 31, ... , "The poor economic environment had an impact ...
... led by Clifford Goodman, PhD, at the NCCN 14th Annual ... Cancer Care." The panel of experts tackled the spectrum of ... benefit to patients of some of the latest cancer treatments ... Oncology is an area of rapid growth, both in terms ...
Cached Medicine News:Health News:Important new model shows how proteins find the right DNA sequences 2Health News:Dendritic cells ensure immune tolerance 2Health News:Dendritic cells ensure immune tolerance 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 2Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 3Health News:Heska Announces Q4 and Annual 2008 Results 2Health News:Heska Announces Q4 and Annual 2008 Results 3Health News:Heska Announces Q4 and Annual 2008 Results 4Health News:Heska Announces Q4 and Annual 2008 Results 5Health News:Heska Announces Q4 and Annual 2008 Results 6Health News:Heska Announces Q4 and Annual 2008 Results 7Health News:Heska Announces Q4 and Annual 2008 Results 8Health News:Heska Announces Q4 and Annual 2008 Results 9Health News:Heska Announces Q4 and Annual 2008 Results 10Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 2Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 3Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 4Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 5
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
Quality control ampoules are specifically developed for Radiometers analyzers , Different parameter profiles (different combinations of blood gases, oximetry, electrolytes and metabolites) , Co...
... In interventional cardiology, accurate ... role, particularly in determining the ... With Interventional Cardiac 3-D (IC3D), ... imaging tool, clinicians are now ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... Hybrid Imaging in Cardiology ... imaging solutions in cardiology. ... coronary CT angiography imaging combined ... Symbia TruePoint SPECTCT combines ...
Medicine Products: